327 related articles for article (PubMed ID: 8725384)
1. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
4. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
5. An overview of progress in antisense therapeutics.
Crooke ST
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
[No Abstract] [Full Text] [Related]
6. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
8. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
Henry SP; Geary RS; Yu R; Levin AA
Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
[TBL] [Abstract][Full Text] [Related]
9. Antisense strategies.
Crooke ST
Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: is the glass half full or half empty?
Bennett CF
Biochem Pharmacol; 1998 Jan; 55(1):9-19. PubMed ID: 9413924
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide derivatives as gene-targeted drugs.
Knorre DG; Vlassov VV
Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
[TBL] [Abstract][Full Text] [Related]
12. Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK; Levin AA
Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
[TBL] [Abstract][Full Text] [Related]
13. Development of antisense oligodeoxynucleotides for transplantation.
Stepkowski SM
Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
[TBL] [Abstract][Full Text] [Related]
14. An overview of sugar-modified oligonucleotides for antisense therapeutics.
Prakash TP
Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide technology: from EST to therapeutics.
Giles RV
Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
[TBL] [Abstract][Full Text] [Related]
16. Antisense treatments for biothreat agents.
Warfield KL; Panchal RG; Aman MJ; Bavari S
Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide therapy.
Crooke ST
Curr Opin Biotechnol; 1992 Dec; 3(6):656-61. PubMed ID: 1369122
[TBL] [Abstract][Full Text] [Related]
19. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective inhibition of gene expression by an antisense heptanucleotide.
Wagner RW; Matteucci MD; Grant D; Huang T; Froehler BC
Nat Biotechnol; 1996 Jul; 14(7):840-4. PubMed ID: 9631007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
